Sorry, you need to enable JavaScript to visit this website.
Skip to main content

This site is intended for US healthcare professionals only.

This site is intended for US healthcare professionals only.

Find BREXAFEMME at a pharmacy near you

Use the tool below to find a pharmacy that offers pickup and/or home
delivery of BREXAFEMME—at no additional cost.



Pharmacies near you

There don't seem to be any pharmacies in your selected radius.

Phil logo

PhilRx makes it easy to get a
BREXAFEMME prescription delivered to your home.

View the instructions below to get started. If you’re a healthcare provider, you can download instructions to share with your patient.

FOR HEALTHCARE PROVIDERS

Download PhilRx Instructions

Need more info to get your
patient started on BREXAFEMME?

Explore Resources

Cure the yeast infection for less.1,2

See Savings Offer

SAY NO MORE to vaginal yeast infections.
Prescribe BREXAFEMME today.

SAY NO MORE to vaginal yeast infections. Prescribe BREXAFEMME today.

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References

1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Data on file. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

/ / / /
  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

Read full Important Safety Information